BiotechTube
Welwaze Medical

Welwaze Medical

Miami, United States· Est.
welwaze.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.5M

Overview

Welwaze Medical is a private, commercial-stage digital health company focused on breast cancer detection through its flagship product, Celbrea®, a thermal biomarker device. The company integrates a medical device, a mobile application, and AI on a blockchain-powered platform to provide adjunctive tools for physicians and patients. Led by founder and CEO Alex J. Ness, Welwaze has garnered several innovation awards and is positioned to disrupt the breast cancer diagnostics market with its human-first, technology-driven approach.

OncologyWomen's Health

Technology Platform

Integrated system combining a thermal imaging medical device (Celbrea®), a mobile application for guidance and monitoring, and artificial intelligence for data analysis, built on a blockchain-powered platform for secure data management.

Funding History

1
Total raised:$1.5M
Seed$1.5M

Opportunities

The large, global breast cancer screening market presents a significant opportunity for adjunctive, patient-friendly tools.
Welwaze's integrated digital platform could improve early detection rates, especially in between routine mammograms, and address healthcare disparities by increasing access to monitoring technology.
The blockchain and AI components offer potential for valuable data aggregation and advanced analytics services.

Risk Factors

Key risks include the need for robust clinical validation to gain medical community acceptance, challenges in securing insurance reimbursement, and intense competition in the digital breast health space.
As a private company with a single commercial product, it also faces execution and financial risks related to scaling operations and achieving sustainable revenue.

Competitive Landscape

Welwaze competes in the digital breast health market, which includes other mobile apps for self-examination reminders, wearable sensors, and other adjunctive screening devices (e.g., ultrasound patches, other thermal imaging systems). Its primary competition comes from established screening methods (mammography, MRI) and skepticism towards the clinical utility of alternative monitoring technologies.

More companies in Small Molecule Drugs →More companies in United States →